SyntekaBio Past Earnings Performance
Past criteria checks 0/6
SyntekaBio has been growing earnings at an average annual rate of 7%, while the Healthcare Services industry saw earnings growing at 13.8% annually. Revenues have been declining at an average rate of 25% per year.
Key information
7.0%
Earnings growth rate
9.9%
EPS growth rate
| Healthcare Services Industry Growth | 16.7% |
| Revenue growth rate | -25.0% |
| Return on equity | -30.6% |
| Net Margin | -7,447.5% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How SyntekaBio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 126 | -9,417 | 7,504 | 3,220 |
| 31 Dec 23 | 123 | -11,398 | 7,477 | 3,225 |
| 30 Sep 23 | 45 | -2,268 | 7,804 | 3,474 |
| 30 Jun 23 | 91 | -11,254 | 7,920 | 3,079 |
| 31 Mar 23 | 169 | -6,745 | 7,931 | 2,728 |
| 31 Dec 22 | 244 | -4,506 | 7,456 | 3,177 |
| 30 Sep 22 | 306 | -9,112 | 6,414 | 3,713 |
| 30 Jun 22 | 324 | -8,759 | 6,000 | 3,709 |
| 31 Mar 22 | 321 | -13,650 | 5,004 | 3,782 |
| 31 Dec 21 | 317 | -14,803 | 4,828 | 3,101 |
| 31 Dec 20 | 610 | -6,488 | 4,417 | 2,108 |
Quality Earnings: A226330 is currently unprofitable.
Growing Profit Margin: A226330 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A226330 is unprofitable, but has reduced losses over the past 5 years at a rate of 7% per year.
Accelerating Growth: Unable to compare A226330's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A226330 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (3.2%).
Return on Equity
High ROE: A226330 has a negative Return on Equity (-30.62%), as it is currently unprofitable.